ChoA Pharmaceutical Co Ltd banner
C

ChoA Pharmaceutical Co Ltd
KOSDAQ:034940

Watchlist Manager
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Watchlist
Price: 550 KRW -1.08% Market Closed
Market Cap: ₩17B

Intrinsic Value

The intrinsic value for ChoA Pharmaceutical Co Ltd (034940) under the Base Case is 1 012.93 KRW. Compared with the current market price of 550 KRW, the stock appears Undervalued by 46% .

Intrinsic value calculated using DCF
₩1 012.93
Other reference points

Do our valuations actually work? See backtest results .

Intrinsic Value
1 012.93
Undervaluation 46%
Intrinsic Value
Price ₩550
C
Monitor ChoA Pharmaceutical Co Ltd
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value ₩810.35
Get notified when the price drops into your buy zone
Intrinsic Value ₩1 012.93
Margin of Safety 20% ₩810.35
Current Price ₩550
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about ChoA Pharmaceutical Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ChoA Pharmaceutical Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for ChoA Pharmaceutical Co Ltd.

Explain Valuation
Alternatives to ChoA Pharmaceutical Co Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one ChoA Pharmaceutical Co Ltd stock?

The intrinsic value for ChoA Pharmaceutical Co Ltd (034940) under the Base Case is 1 012.93 KRW.

Is ChoA Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared with the current market price of 550 KRW, the stock appears Undervalued by 46% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett